$Fireman B.V.(IFRX)$ IFX-1 tre_老虎社区_美港股上老虎

TLBiotech
2020-06-17

IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe ** pneumonia
InflaRx is now evaluating the continuation into a placebo-controlled Phase III part of the trial with 28-day all-cause mortality as the primary endpoint

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":955635729,"tweetId":"955635729","gmtCreate":1592396116961,"gmtModify":1704199139055,"author":{"id":3524115374349406,"idStr":"3524115374349406","authorId":3524115374349406,"authorIdStr":"3524115374349406","name":"TLBiotech","avatar":"https://static.tigerbbs.com/9712e908fe753ed0c55dd93cb4258804","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":8,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>\n<a href=\"https://laohu8.com/S/IFRX\">$Fireman B.V.(IFRX)$</a><ul>\n <li>IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe ** pneumonia<br>&nbsp;</li>\n <li>InflaRx is now evaluating the continuation into a placebo-controlled Phase III part of the trial with 28-day all-cause mortality as the primary endpoint</li>\n</ul></body></html>","htmlText":"<html><head></head><body>\n<a href=\"https://laohu8.com/S/IFRX\">$Fireman B.V.(IFRX)$</a><ul>\n <li>IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe ** pneumonia<br>&nbsp;</li>\n <li>InflaRx is now evaluating the continuation into a placebo-controlled Phase III part of the trial with 28-day all-cause mortality as the primary endpoint</li>\n</ul></body></html>","text":"$Fireman B.V.(IFRX)$ IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe ** pneumonia InflaRx is now evaluating the continuation into a placebo-controlled Phase III part of the trial with 28-day all-cause mortality as the primary endpoint","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/955635729","repostId":0,"isVote":1,"tweetType":1,"viewCount":2362,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["IFRX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":345,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}